Will Quantum and 6G Innovations Transform Keysight Technologies’ (KEYS) Competitive Edge?

• Over the past two weeks, Keysight Technologies announced the launch of its Quantum System Analysis EDA solution, expanded its high-power test equipment portfolio, and revealed a collaboration with MediaTek to advance pre-6G integrated sensing and communication technologies.
• These developments showcase Keysight's rapid innovation in quantum computing, test automation, and next-generation wireless standards, reinforcing its position at the forefront of technical measurement solutions in high-growth sectors.
• We'll explore how Keysight's fresh advances in quantum simulation and 6G research could influence its long-term investment outlook.

Find companies with promising cash flow potential yet trading below their fair value.

Keysight Technologies Investment Narrative Recap

To own Keysight Technologies, an investor needs to believe the company can consistently drive growth by advancing its leadership in automated testing, next-gen wireless, and quantum solutions while managing emerging cost pressures and end-market volatility. The recent innovations in quantum EDA and 6G research highlight Keysight's R&D strengths but do not materially alter the near-term focus: successfully offsetting the impact of higher tariffs remains the most important short-term catalyst, while execution on cost mitigation stands as the biggest risk.

Among the latest developments, the introduction of the high-power ATE system power supplies is especially relevant, as it expands Keysight's core offering in automated validation for high-power devices, supporting customer shifts toward electrification and energy efficiency. This aligns closely with a major growth catalyst around automation-driven demand in both electronics and automotive, providing tools that address power density, automation, and sustainability, all issues heightened by evolving industry complexity.

Yet, in contrast, investors should be aware that Keysight's current cost mitigation efforts in response to new tariffs face challenges that could...

Read the full narrative on Keysight Technologies (it's free!)

Keysight Technologies is forecast to achieve $6.3 billion in revenue and $1.2 billion in earnings by 2028. This outlook is based on a 6.5% annual revenue growth rate and a $656 million increase in earnings from the current level of $544 million.

Uncover how Keysight Technologies' forecasts yield a $187.60 fair value, a 4% upside to its current price.

Exploring Other Perspectives

Five fair value estimates from the Simply Wall St Community range widely, from US$141.36 to US$190.01 per share. While automation-driven demand offers reasons for optimism, differing views remind you that Keysight’s business performance can be weighed down by persistent cost risks, so check the alternatives.

Explore 5 other fair value estimates on Keysight Technologies - why the stock might be worth 22% less than the current price!

Build Your Own Keysight Technologies Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Keysight Technologies research is our analysis highlighting 1 key reward and 1 important warning sign that could impact your investment decision.
• Our free Keysight Technologies research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Keysight Technologies' overall financial health at a glance.

Ready For A Different Approach?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• We've found 16 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
• These 12 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com